An orphan drug framework (ODF) for Canada

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 21, Issue 1, 2014, Pages

  Lee, David K ^a   Wong, Barbara ^a  

^a Health Canada and World Health Organization Collaborating Center for Standardization and Evaluation of Biologicals

Author keywords

Canada; Orphan drug; Regulation

Indexed keywords

ORPHAN DRUG;

ARTICLE; CANADA; CLINICAL TRIAL (TOPIC); DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MARKET; RARE DISEASE; DRUG MANUFACTURE; LEGISLATION AND JURISPRUDENCE; RARE DISEASES;

CANADA; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84895812069     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Orphanet, last updated: 2013, About Rare Diseases. http://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN (August 30, 2013)
2. European Commission Health and Consumer Protection Directorate-General, Rare diseases: Europe's challenges, document for consultation, end date: February 14, 2008. http://ec.europa.eu/health/ph_threats/non_com/docs/raredis_comm_draft.pdf (August 30, 2013)
3. Canadian Organization for Rare Disorders website, last updated: 2013, About Us. http://raredisorders.ca/aboutUs.html (August 30, 2013)
4. Orphanet, last updated: 2009, Duchenne muscular dystrophy. http://www.orpha.net/consor/cgi-bin/Disease_Search_Simple.php?lng=EN (August 30, 2013)
5. CHEO Research Institute website, last updated: 2012, Genetics Overview. http://www.cheori.org/en/geneticsresearchOverview (August 30, 2013)
6. Canadian Institutes for Health Research website, last updated: 2012, Harper Government supports research on rare diseases. http://www.cihr-irsc.gc.ca/e/44944.html (October 30, 2013)
7. Health Canada website, last updated: 2012, Harper Government Takes Action to Help Canadians with Rare Diseases. http://hcsc.gc.ca/ahc-asc/media/nr-cp/_2012/2012-147-eng.php (October 30, 2013)
8. US Government Printing Office, 21 CFR Part 316-Orphan Drugs. http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=51cf70689d51f0ea4147c0a8ac649321&rgn=div5&view=text&node=21:5.0.1.1.6&idno=21 (August 30, 2013)
9. US Food and Drug Administration website, Orphan Products Grants Program. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/OrphanDrugAct/default.htm (August 30, 2013)
10. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF (August 30, 2013)
11. European Medicines Agency, Fee reductions for designated orphan medicinal products. December 6, 2012, http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/02/WC500102327.pdf (August 30, 2013)
12. European Medicines Agency, Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000 of the European Parliament and of the Council: Review of the period of market exclusivity of orphan medicinal products 2008. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:242:0008:0011:EN:PDF (August 30, 2013)
13. US Food and Drug Administration website, Developing Products for Rare Diseases & Conditions, updated: 2013, http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm (August 30, 2013)
14. Heger M. Despite surge in orphan drug designations, approvals still lag. Nature Medicine 2011;17:236.
15. The Committee for Orphan Medicinal Products and the European Medicines Agency Scientific Secretariat. European regulation on orphan medicinal products: 10 years of experience and future perspectives. Nature Reviews Drug Discovery 2011;10:341.
16. US Food and Drug Administration website, Search Orphan Drug Designations and Approvals, http://www.accessdata.fda.gov/scripts/opdlisting/oopd/ (October 30, 2013)
17. Health Canada website, last updated: 2013, Drug Product Database. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php (October 30, 2013)
18. Health Canada, Special Access Programme database. (June 7, 2013)
19. Office of the Auditor General of Canada, 2011 Fall Report of the Auditor General of Canada, Ch. 4-Regulating Pharmaceutical Drugs-Health Canada, http://www.oag-bvg.gc.ca/internet/english/parl_oag_201111_04_e_35936.html (August 30, 2013)
20. The Standing Senate Committee on Social Affairs, Science and Technology, Canada's Clinical Trial Infrastructure: A Prescription for Improved Access to New Medicines, November 2012. http://www.parl.gc.ca/Content/SEN/Committee/411/soci/rep/rep14nov12-e.pdf (August 30, 2013)
21. The Standing Senate Committee on Social Affairs, Science and Technology, Prescription Pharmaceuticals in Canada: Post-Approval Monitoring of Safety and Effectiveness, February 2013. http://parl.gc.ca/Content/SEN/Committee/411/SOCI/rep/rep20mar13-e.pdf (August 30, 2013)
22. European Medicines Agency website, Committee for Orphan Medicinal Products-strengthened interactions with patients and international partners. February 14, 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/02/news_detail_001718.jsp&mid=WC0b01ac058004d5c1 (August 30, 2013)
23. Canadian Agency for Drugs and Technologies in Health website, Patient input, last updated: 2013. http://www.cadth.ca/en/products/cdr/patient-group-input/ (August 30, 2013)